Navigation Links
Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses

Vaccine Has Potential to Save Millions of Lives

GERMANTOWN, Md., Oct. 7 /PRNewswire/ -- Integrated BioTherapeutics Inc. (IBT), a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, announced they have been awarded a multiyear contract for advanced development of a vaccine to protect against Ebola and Marburg viruses from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract is valued at approximately $22 million, which, if options are exercised, could total up to $65 million.

Considered a significant bioterrorist threat, Ebola and Marburg lead to death 30-90 percent of the time they are contracted, and there are currently no vaccines or therapeutics available for treatment of humans infected with either virus. Ebola and Marburg virus outbreaks typically occur in resource poor areas in Sub-Saharan Africa, although rare cases have occurred in the United States, Europe and the Philippines. Filoviruses are also a source of concern as potential bioterror agents.

"We are very pleased that NIAID has awarded such a significant contract to fund the advanced development activities for our virus-like particle vaccine against Ebola and Marburg viruses. This is a significant step forward in our mission to improving public health and developing medical countermeasures for biodefense. This contract will fund a major portion of the preclinical and clinical activities required to confirm and refine the activity in animals and verify the activity in humans," commented Dr. Javad Aman, IBT President and Chief Scientific Officer.

IBT is collaborating with colleagues at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop a subunit vaccine, based on the virus-like particles, with broad-spectrum activity toward different strains of Ebola and Marburg viruses. Other collaborating organizations include Protein Sciences Corporation, Meriden, Conn.; Aridis Pharmaceuticals, San Jose, Calif.; Baylor College of Medicine, Houston, Tex.; and AMAR International, Fairfax, Va.

The ultimate objective of the government's program is to develop a safe and effective vaccine to protect against the Zaire, Sudan and Cote d'Ivoire strains of Ebola virus as well as multiple isolates of Marburg virus. The vaccine, to be developed by IBT, provides broad protection in nonhuman primates. The virus-like particle vaccines are strikingly similar to the authentic virus and were originally developed by IBT's founders and their colleagues at USAMRIID.

Initially, IBT will receive approximately $22 million to conduct preclinical activities, including preclinical efficacy animal studies, development and qualification of assays, formulation studies and process development for manufacturing activities. After preclinical studies, NIAID may exercise options to the contract that include cGMP manufacturing, Phase 1 clinical trial, scale-up of cGMP manufacturing, lyophylized formulation and a Phase 2 clinical trial The potential value of the entire contract if all the options are exercised by the government, is $65.2 million.

About Integrated BioTherapeutics Inc.:

Integrated BioTherapeutics Inc. (IBT) is an emerging research-based company dedicated to development of vaccines, immunotherapeutics, and discovery of small molecules targeting emerging infectious agents. IBT is located in Germantown, Maryland. IBT has a portfolio of proprietary recombinant technologies for development of vaccines and immunotherapeutics against major biodefense and emerging infectious agents, with an emphasis on staphylococcal, and streptococcal infections, as well as viral hemorrhagic fevers. IBT has experience and a close working arrangement with many of the United States government agencies including the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), National Cancer Institute (NCI), National Institute of Health (NIH), and the Department of Defense (DOD). Furthermore, IBT has established cooperative working relationships with several universities, as well as pharmaceutical and biotechnology companies for development of joint products for prevention and treatment of staphylococcal infections and viral hemorrhagic fevers.

For more information about IBT, please visit

SOURCE Integrated BioTherapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
4. Chiltern Early Phase: Fully Integrated and Business Ready
5. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
6. A first in integrated nanowire sensor circuitry
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
10. Augusta Systems Technologies Integrated into Ciscos Newly Launched Safety and Security Platform
11. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ... Laurin , President and Chief Executive Officer of ProMetic, will ... 27 th Annual Healthcare Conference to be held at ... st , at 8.50am (ET) and ProMetic,s management ... The presentation will be available live via a webcast accessible ...
(Date:11/24/2015)... , November 24, 2015 , ... a European healthcare fund ... companies will work closely together in identifying European breakthrough technologies ... need. The collaboration is underpinned by a significant investment by ... is the first investment by Bristol-Myers Squibb in a European ...
(Date:11/23/2015)... 23, 2015   Ceres, Inc . (Nasdaq: ... results for the fiscal year ended August 31, 2015 ... --> --> During fiscal year ... feed products with a better balance of yield, energy ... agreements with several leading crop input providers and made ...
Breaking Biology Technology:
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):